11:14:43 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-03-21 Ordinarie utdelning FLUO 0.00 DKK
2024-03-20 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-29 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-03-22 Ordinarie utdelning FLUO 0.00 DKK
2023-03-21 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-19 Ordinarie utdelning FLUO 0.00 DKK
2022-05-18 Årsstämma 2022
2022-03-30 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning FLUO 0.00 DKK
2021-02-26 Bokslutskommuniké 2020
2021-02-09 Årsstämma 2021
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-14 Kvartalsrapport 2020-Q2
2020-05-27 Kvartalsrapport 2020-Q1
2020-04-09 Ordinarie utdelning FLUO 0.00 DKK
2020-04-08 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-05-31 Kvartalsrapport 2019-Q1

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
FluoGuide är ett danskt bolag verksamma inom medicinteknik. Bolaget affärsfokus återfinns inom forskning och utveckling av behandlingar mot olika cancerformer, med störst fokus på utveckling av produkter som vägleder vid kirurgiska ingrepp. Produkterna binder till sig cancercellerna som då lyser upp och är avsedda att användas för att med precision kunna ta bort skadliga tumörer i patientens vävnad.
2021-11-01 11:25:27
Copenhagen, Denmark, 1 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today is pleased to announce the initiation of the preclinical development of FG002 in fluorescent-guided surgery for cancer.

The initiation of the preclinical development of FG002 broadens FluoGuide’s portfolio of uPAR-targeted products with features unique to IRDye® 800CW. FluoGuide is therefore well-positioned to maximize the clinical and commercial potential of uPAR-targeted products in fluorescent-guided surgery for cancer.

FG002 is made of two components, the uPAR binding molecule which targets cancerous cells specifically, and a fluorophore that lights up those cells. IRDye® 800CW infrared dye is a novel fluorophore that due to its brightness, enables deep visibility. FluoGuide expects that FG002 can be useful for guiding the surgical treatment for prevalent cancer indications such as colorectal cancer. The final selection of the first indication is decided prior to initiation of the first clinical trial anticipated to be a phase I/II trial with the primary end-end point being safety but as well providing first evidence of efficacy.

FluoGuide has on the basic of positive data from animal studies decided to initiate the preclinical development.

“The initiation of the preclinical development further substantiates FluoGuide’s strategy of developing a multiple-products, multiple indications portfolio that maximizes surgical outcome in cancer treatment based on FluoGuide’s patented uPAR-targeting technology platform” says Morten Albrechtsen, CEO.

“The initiation of the preclinical development of FG002 with distinct differences in features compared to FG001 will also provide FluoGuide with enhanced flexibility in pricing and partnering”